Outlook Therapeutics
Outlook Therapeutics, Inc.
Outlook Therapeutics is a pioneering biopharmaceutical company specializing in the development and commercialization of ophthalmic medications. The company is committed to addressing significant unmet medical needs in the treatment of retinal diseases through innovative therapeutic solutions.
Products & Team
ONS-5010/LYTENAVA™ (bevacizumab-vikg)
This product is an innovative ophthalmic formulation of bevacizumab specifically designed to meet FDA standards. It is intended for the treatment of various retinal diseases, particularly wet age-related macular degeneration.
ONS-5010/LYTENAVA™ offers a clinically validated and regulation-compliant alternative for ophthalmologists treating retinal diseases, fulfilling the need for a safe and approved therapy option.
The need for FDA-approved, reliable, and effective treatments for complex retinal diseases such as wet AMD, to reduce the dependence on off-label drug solutions.